These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8626112)

  • 1. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study.
    Currie J; Blessing JA; Muss HB; Fowler J; Berman M; Burke TW
    Gynecol Oncol; 1996 Apr; 61(1):27-30. PubMed ID: 8626112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
    Currie JL; Blessing JA; McGehee R; Soper JT; Berman M
    Gynecol Oncol; 1996 Apr; 61(1):94-6. PubMed ID: 8626125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.
    Edmonson JH; Marks RS; Buckner JC; Mahoney MR
    Cancer Invest; 2002; 20(5-6):605-12. PubMed ID: 12197215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study.
    Long HJ; Blessing JA; Sorosky J
    Gynecol Oncol; 2005 Nov; 99(2):339-42. PubMed ID: 16051328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
    Pautier P; Genestie C; Fizazi K; Morice P; Mottet C; Haie-Meder C; Le Cesne A; Lhommé C
    Int J Gynecol Cancer; 2002; 12(6):749-54. PubMed ID: 12445254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Rose PG; Blessing JA; Soper JT; Barter JF
    Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR; Salzman D; Boldt D; Kuhn J; Irvin R; Roodman GD; Lyons R; Smith L; Freytes CO; LeMaistre CF
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L
    Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing JA; Malfetano JH
    Gynecol Oncol; 1996 Aug; 62(2):226-9. PubMed ID: 8751554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma.
    Philip PA; Carmichael J; Tonkin K; Ganesan TA; Harris AL
    Eur J Cancer; 1994; 30A(7):1027-9. PubMed ID: 7946568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
    Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA
    Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
    Minobe S; Todo Y; Suzuki Y; Aoyagi Y; Umazume T; Okamoto K; Kato H
    J Obstet Gynaecol Res; 2011 Jun; 37(6):645-9. PubMed ID: 21375676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.
    Edmonson JH; Blessing JA; Cosin JA; Miller DS; Cohn DE; Rotmensch J
    Gynecol Oncol; 2002 Jun; 85(3):507-10. PubMed ID: 12051882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.
    Van Tine BA; Ingham MA; Attia S; Meyer CF; Baird JD; Brooks-Asplund E; D'Silva D; Kong R; Mwatha A; O'Keefe K; Weetall M; Spiegel R; Schwartz GK
    J Clin Oncol; 2024 Jul; 42(20):2404-2414. PubMed ID: 38684039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
    Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
    Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant uterine smooth muscle tumors: role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy.
    Resnik E; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE; Chambers IT
    J Surg Oncol; 1996 Nov; 63(3):145-7. PubMed ID: 8944057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group.
    Thigpen JT; Blessing JA; Wilbanks GD
    Am J Clin Oncol; 1986 Feb; 9(1):18-20. PubMed ID: 3953489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma.
    Yeh KH; Lu YS; Hsiao CH; Cheng AL
    Anticancer Res; 2003; 23(6D):5133-7. PubMed ID: 14986591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Beecham J; Homesley H; Yordan E
    J Clin Oncol; 1991 Nov; 9(11):1962-6. PubMed ID: 1941054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.